Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14224538 | 0.89 | AVPR2 (0.45) | MCHR1KDRSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL14224529 | 0.78 | FOXO1 (0.41) | MCHR1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL14427754 | 0.78 | L3MBTL1 (0.42) | PDE10ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL14224681 | 0.68 | CYP11B2 (0.46) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL14455744 | 0.68 | TOP1 (0.42) | — | |
| SCHEMBL4338344 | 0.66 | CTSD (0.65) | MCHR1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2817441 | 0.66 | HTR6 (0.51) | — | |
| SCHEMBL927338 | 0.65 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1MAPTMAPK1HSD17B10 | |
| SCHEMBL30675620 | 0.65 | ALDH1A1 (0.62) | SMN1; SMN2ALDH1A1MAPTMAPK1HSD17B10 | |
| Hydrochloric Acid SCHEMBL10990786 | 0.64 | ALDH1A1 (0.61) | SMN1; SMN2ALDH1A1MAPTMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7265129-B2 | Anti-infective biaryl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | QTRT1, Q6ZSR9, QTRT2 | MCHR1 2722/4885PDE10A 4438/4885FGFR3 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.